Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rebutting oral tolerance warnings

Rebutting oral tolerance warnings

Two reports appearing in this month's Science raised red flags about the potential of oral tolerance therapy for autoimmune diseases to backfire. But the models used by the researchers may not be relevant to the way in which oral tolerance therapy is actually administered. In addition, the problems seen in the animal models haven't shown up in the 1,400 patients treated thus far in

Read the full 685 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers